These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22109829)

  • 21. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
    Wang LH; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
    Li WY; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
    Ruvolo PP; Ruvolo VR; Jacamo R; Burks JK; Zeng Z; Duvvuri SR; Zhou L; Qiu Y; Coombes KR; Zhang N; Yoo SY; Pan R; Hail N; Konopleva M; Calin G; Kornblau SM; Andreeff M
    Biochim Biophys Acta; 2014 Sep; 1843(9):1969-77. PubMed ID: 24858343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells.
    Liao Y; Hung MC
    Cancer Res; 2004 Sep; 64(17):5938-42. PubMed ID: 15342371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
    Estella-Hermoso de Mendoza A; Castello-Cros R; Imbuluzqueta E; Cirauqui C; Pippa R; Odero MD; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2015 Apr; 11(4):691-701. PubMed ID: 26310075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
    Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Scanning of c-kit gene mutations in acute myeloid leukemias using high-resolution melting analysis].
    Yao DM; Qian J; Lin J; Chen Q; Xiao GF; Wang YL; Qian Z; Ji RB; Li Y; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):21-4. PubMed ID: 21429396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia.
    Gao XN; Lin J; Gao L; Li YH; Wang LL; Yu L
    Leuk Res; 2011 Sep; 35(9):1226-32. PubMed ID: 21724256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.
    Lasa A; Carricondo MT; Carnicer MJ; Perea G; Aventín A; Nomdedeu JF
    Haematologica; 2006 Sep; 91(9):1283-4. PubMed ID: 16956837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
    Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
    Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
    Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
    Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.